Current controversy related to glucocorticoid and insulin therapy in the intensive care unit

Endocrine Practice

Volumn 13, Issue 5, 2007, Pages 542-549

  Klaff, Lindy S ^a   Wisse, Brent E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOCORTICOID; INSULIN;

CRITICAL ILLNESS; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; METHODOLOGY; REVIEW;

CRITICAL CARE; CRITICAL ILLNESS; GLUCOCORTICOIDS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INTENSIVE CARE UNITS;

EID: 35148893634     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.13.5.542     Document Type: Review

References (78)

1. Brown-Séquard C. Recherches expérimentales sur la physiologie et la pathologie des capsules surrénales. C R Acad Sci. 1856;43:422-425.
2. Perla D, Marmorston J. Suprarenal cortical hormone and salt in the treatment of pneumonia and other severe infections. Endocrinology. 1940;27:367-374.
3. The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med. 1987;317:659-665.
4. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317:653-658.
5. Vincent JL, Abraham E. The last 100 years of sepsis. Am J Respir Crit Care Med. 2006;173:256-263.
6. Moran JL, Chapman MJ, O'Fathartaigh MS, Peisach AR, Pannall PR, Leppard P. Hypocortisolaemia and adrenocortical responsiveness at onset of septic shock. Intensive Care Med. 1994;20:489-495.
7. Drucker D, Shandling M. Variable adrenocortical function in acute medical illness. Crit Care Med, 1985;13:477-479.
8. Annane D, Sébille V, Troché G, Raphaël JC, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA. 2000;283:1038-1045.
9. Annane D, Bellissant E, Sebille V, et al. Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve. Br J Clin Pharmacol. 1998;46:589-597.
10. Bouachour G, Tirot P, Gouello JP, Mathieu E, Vincent JF, Alquier P. Adrenocortical function during septic shock. Intensive Care Med. 1995;21:57-62.
11. Annane D, Sébille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288:862-871.
12. Dellinger RP, Carlet JM, Masur H, et al (Surviving Sepsis Campaign Management Guidelines Committee). Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock [errata in Crit Care Med. 2004;32:1448 and Crit Care Med. 2004;32:2169-2170]. Crit Care Med. 2004;32:858-873.
13. Rady MY, Johnson DJ, Patel B, Larson J, Helmers R. Cortisol levels and corticosteroid administration fail to predict mortality in critical illness: the confounding effects of organ dysfunction and sex. Arch Surg. 2005;140:661-668.
14. Zaloga GP, Marik P. Hypothalamic-pituitary-adrenal insufficiency. Crit Care Clin. 2001;17:25-41.
15. Goldberg PA, Inzucchi SE. Critical issues in endocrinology. Clin Chest Med. 2003;24:583-606.
16. Nieboer P, van der Werf TS, Beentjes JA, Tulleken JE, Zijlstra JG, Ligtenberg JJ. Catecholamine dependency in a polytrauma patient: relative adrenal insufficiency? Intensive Care Med. 2000;26:125-127.
17. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med. 2003;348:727-734.
18. Beishuizen A, Thijs LG, Vermes I. Patterns of corticosteroid- binding globulin and the free cortisol index during septic shock and multitrauma. Intensive Care Med. 2001;27:1584-1591.
19. Ho JT, Al-Musalhi H, Chapman MJ, et al. Septic shock and sepsis: a comparison of total and free plasma cortisol levels. J Clin Endocrinol Metab. 2006;91:105-114.
20. Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. N Engl J Med. 2004;350:1629-1638.
21. Annane D, Maxime V, Ibrahim F, Alvarez JC, Abe E, Boudou P. Diagnosis of adrenal insufficiency in severe sepsis and septic shock. Am J Respir Crit Care Med. 2006;174:1319-1326.
22. Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab. 1981;53:58-68.
23. Aron D. Diagnostic implications of adrenal physiology and clinical epidemiology for evaluation of glucocorticoid excess and deficiency. In: DeGroot LJ, Jameson JL, eds. Endocrinology. 4th ed. Philadelphia, PA: WB Saunders Co., 2000.
24. Widmer IE, Pruder JJ, König C, et al. Cortisol response in relation to the severity of stress and illness. J Clin Endocrinol Metab. 2005;90: 4579-4586.
25. Dimopoulou I, Zervou M, Douka E, Augustatou C, Armaganidis A, Tsagarakis S. Reproducibility of the corticotropin stimulation test in septic shock. Anesth Analg. 2006;103:1056-1057.
26. Loisa P, Uusaro A, Ruokonen E. A single adreno-corticotropic hormone stimulation test does not reveal adrenal insufficiency in septic shock. Anesth Analg. 2005;101:1792-1798.
27. Van den Berghe G, de Zegher F, Bouillon R. Clinical review 95: acute and prolonged critical illness as different neuroendocrine paradigms. J Clin Endocrinol Metab. 1998;83:1827-1834.
28. May ME, Carey RM. Rapid adrenocorticotropic hormone test in practice. Retrospective review. Am J Med. 1985;79:679-684.
29. Speckart PF, Nicoloff JT, Bethune JE. Screening for adrenocortical insufficiency with cosyntropin (synthetic ACTH). Arch Intern Med. 1971;128:761-763.
30. Grinspoon SK, Biller BM. Clinical review 62: laboratory assessment of adrenal insufficiency. J Clin Endocrinol Metab. 1994;79:923-931.
31. Lipiner-Friedman D, Sprung CL, Laterre PF, et al. Adrenal function in sepsis: the retrospective Corticus cohort study. Crit Care Med. 2007;35:1012-1018.
32. Coolens JL, Van Baelen H, Heyns W. Clinical use of unbound plasma cortisol as calculated from total cortisol and corticosteroid-binding globulin. J Steroid Biochem. 1987;26:197-202.
33. Wagner RL, White PF, Kan PB, Rosenthal MH, Feldman D. Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med. 1984;310:1415-1421.
34. Rivers EP, Gaspari M, Saad GA, et al. Adrenal insufficiency in high-risk surgical ICU patients. Chest. 2001;119:889-896.
35. Badder EM, Santen R, Samojlik E, Harrison TS. Adrenal medullary epinephrine secretion: effects of cortisol alone and combined with aminoglutethimide. J Lab Clin Med. 1980;96:815-821.
36. Boumpas DT, Chrousos G, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med. 1993;119:1198-1208.
37. Bateman A, Singh A, Kral T, Solomon S. The immunehypothalamic- pituitary-adrenal axis. Endocr Rev. 1989;10:92-112.
38. Cohen JJ. Glucocorticoid-induced apoptosis in the thymus. Semin Immunol. 1992;4:363-369.
39. Keh D, Boehnke T, Weber-Cartens S, et al. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med. 2003;167:512-520.
40. Oppert M, Schindler R, Husung C, et al. Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med. 2005;33:2457-2464.
41. Vermes I, Beishuizen A. The hypothalamic-pituitary-adrenal response to critical illness. Best Pract Res Clin Endocrinol Metab. 2001;15:495-511.
42. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med. 1995;332:1351-1362.
43. Vanhorebeek I, Peeters RP, Vander Perre S, et al. Cortisol response to critical illness: effect of intensive insulin therapy. J Clin Endocrinol Metab. 2006;91:3803-3813.
44. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;345:1359-1367.
45. Krinsley JS. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients [erratum in Mayo Clin Proc. 2005;80:1101]. Mayo Clin Proc. 2004;79:992-1000.
46. Finney SJ, Zekveld C, Elia A, Evans TW. Glucose control and mortality in critically ill patients. JAMA. 2003;290:2041-2047.
47. Pittas AG, Siegel RD, Lau J. Insulin therapy for critically ill hospitalized patients: a meta-analysis of randomized controlled trials. Arch Intern Med. 2004;164:2005-2011.
48. Rady MY, Johnson DJ, Patel BM, Larson JS, Helmers RA. Influence of individual characteristics on outcome of glycemic control in intensive care unit patients with or without diabetes mellitus. Mayo Clin Proc. 2005;80:1558-1567.
49. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449-461.
50. Van den Berghe G, Wilmer A, Milants I, et al. Intensive insulin therapy in mixed medical/surgical intensive care units: benefit versus harm. Diabetes. 2006;55:3151-3459.
51. McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia. Crit Care Clin. 2001;17:107-124.
52. Vanhorebeek I, Langouche L, Van den Berghe G. Glycemic and nonglycemic effects of insulin: how do they contribute to a better outcome of critical illness? Curr Opin Crit Care. 2005;11:304-311.
53. Kim F, Tysseling KA, Rice J, et al. Activation of IKKbeta by glucose is necessary and sufficient to impair insulin signaling and nitric oxide production in endothelial cells. J Mol Cell Cardiol. 2005;39:327-334.
54. Kim F, Tysseling KA, Rice J, et al. Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKbeta. Arterioscler Thromb Vasc Biol. 2005;25:989-994.
55. Van den Berghe G. How does blood glucose control with insulin save lives in intensive care? J Clin Invest. 2004;114:1187-1195.
56. Frankenfield D. Energy expenditure and protein requirements after traumatic injury. Nutr Clin Pract. 2006;21:430-437.
57. Kan MN, Chang HH, Sheu WF, Cheng CH, Lee BJ, Huang YC. Estimation of energy requirements for mechanically ventilated, critically ill patients using nutritional status. Crit Care. 2003;7:R108-R115.
58. Braunschweig CL, Levy P, Sheean PM, Wang X. Enteral compared with parenteral nutrition: a meta-analysis. Am J Clin Nutr. 2001;74:534-542.
59. Gramlich L, Kichian K, Pinilla J, Rodych NJ, Dhaliwal R, Heyland DK. Does enteral nutrition compared to parenteral nutrition result in better outcomes in critically ill adult patients? A systematic review of the literature. Nutrition. 2004;20:843-848.
60. Heuer JG, Bailey DL, Sharma GR, et al. Cecal ligation and puncture with total parenteral nutrition: a clinically relevant model of the metabolic, hormonal, and inflammatory dysfunction associated with critical illness. J Surg Res. 2004;121:178-186.
61. Fariñas-Alvarez C, Fariñas MC, García-Palomo JD, et al. Prognostic factors for pneumococcal bacteremia in a university hospital. Eur J Clin Microbiol Infect Dis. 2000;19:733-741.
62. Wilson M, Weinreb J, Hoo GW. Intensive insulin therapy in critical care: a review of 12 protocols. Diabetes Care. 2007;30:1005-1011.
63. Marik PE, Varon J. Intensive insulin therapy in the ICU: is it now time to jump off the bandwagon? Resuscitation. 2007;74:191-193.
64. Davidson PC, Steed RD, Bode BW. Glucommander: a computer-directed intravenous insulin system shown to be safe, simple, and effective in 120,618 h of operation. Diabetes Care. 2005;28:2418-2423.
65. Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension. 1994;24:571-575.
66. Duprez DA, De Buyzere ML, Rietzschel ER, et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J. 1998;19:1371-1376.
67. Holmes CL, Patel BM, Russell JA, Walley KR. Physiology of vasopressin relevant to management of septic shock. Chest. 2001;120:989-1002.
68. Sharshar T, Carlier R, Blanchard A, et al. Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med. 2002;30:497-500.
69. Krismer AC, Wenzel V, Mayr VD, et al. Arginine vasopressin during cardiopulmonary resuscitation and vasodilatory shock: current experience and future perspectives. Curr Opin Crit Care. 2001;7:157-169.
70. Bornstein SR, Licinio J, Tauchnitz R, et al. Plasma leptin levels are increased in survivors of acute sepsis: associated loss of diurnal rhythm, in cortisol and leptin secretion. J Clin Endocrinol Metab. 1998;83:280-283.
71. Howard JK, Lord GM, Matarese G, et al. Leptin protects mice from starvation-induced lymphoid atrophy and increases thymic cellularity in ob/ob mice. J Clin Invest. 1999;104:1051-1059.
72. deBoisblanc BP. Alpha-melanocyte stimulating hormone in sepsis: is your patient's brain smarter than your patient's doctor? Crit Care Med. 2000;28:1665-1666.
73. Baugh JA, Bucala R. Macrophage migration inhibitory factor. Crit Care Med. 2002;30(Suppl 1):S27-S35.
74. Takala J, Ruokonen E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med. 1999;341:785-792.
75. Brent GA, Hershman JM. Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration. J Clin Endocrinol Metab. 1986;63:1-8.
76. Van den Berghe G, de Zegher F, Bouillon R. The somatotrophic axis in critical illness: effects of growth hormone secretagogues. Growth Horm IGF Res. 1998;8(Suppl B): 153-155.
77. Mesotten D, Van den Berghe G. Changes within the GH/IGF-I/IGFBP axis in critical illness. Crit Care Clin. 2006;22:17-28, v.
78. Debaveye Y, Ellger B, Mebis L, et al. Tissue deiodinase activity during prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone-releasing peptide-2. Endocrinology. 2005;146:5604-5611.